View Older Stories View More Recent Stories

Jan 3, 2022 07:03AM Xeris Pharmaceuticals Inc. (XERS) Enters Into Agreement for $30 Million Private Placement
Jan 3, 2022 07:00AM Xeris Biopharma Enters Into Agreement for $30 Million Private Placement
Dec 30, 2021 04:31PM Xeris Pharmaceuticals Inc. (XERS) Granted FDA Approval for Recorlev to Treat Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome
Dec 30, 2021 04:30PM Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
Dec 16, 2021 07:00AM Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma
Nov 10, 2021 07:00AM Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights
Nov 2, 2021 07:30AM Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021
Oct 25, 2021 07:33AM Xeris Pharmaceuticals Inc. (XERS) Enters Collaboration Agreement With Merck (MRK)
Oct 25, 2021 07:30AM Xeris Pharmaceuticals Enters Collaboration Agreement With Merck
Oct 5, 2021 04:05PM Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
Oct 1, 2021 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 17, 2021 08:00AM Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Sep 14, 2021 04:05PM Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
Sep 7, 2021 04:05PM Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 1, 2021 07:31AM Xeris Pharmaceuticals Inc. (XERS) Phase 1 Levothyroxine Study Enrollment Completed
Sep 1, 2021 07:30AM Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
Aug 30, 2021 07:30AM Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma
Aug 23, 2021 08:02AM Xeris Pharmaceuticals Inc. (XERS) sNDA of Gvoke Approved by FDA
Aug 23, 2021 08:00AM Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia
Aug 19, 2021 08:00AM Xeris Pharmaceuticals Strengthens Its Patent Estate
Aug 13, 2021 08:01AM Xeris Pharmaceuticals Inc. (XERS) announces achievement of important milestone of payor coverage for Gvoke
Aug 13, 2021 08:00AM Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®
Aug 11, 2021 05:10PM Xeris Pharmaceuticals Inc. (XERS) Announces FDA Acceptance of its IND Application for XeriSol Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
Aug 11, 2021 04:05PM Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
Aug 5, 2021 07:00AM Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
Jul 29, 2021 04:05PM Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
Jul 29, 2021 08:30AM Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
Jul 28, 2021 05:14PM Xeris Pharmaceuticals Inc. (XERS) CFO to Step Down
Jul 28, 2021 04:15PM Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success
Jul 19, 2021 08:03AM Xeris Pharmaceuticals Inc. (XERS) Enters Into Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo in Europe
Jul 19, 2021 08:00AM Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
Jul 2, 2021 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 24, 2021 04:58PM Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 24, 2021 07:00AM Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 24, 2021 06:56AM Xeris Pharmaceuticals Inc. (XERS) to Acquire Strongbridge Biopharma (SBBP) in Stock and CVR Transaction
May 24, 2021 06:55AM Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
May 13, 2021 07:00AM Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
May 6, 2021 04:05PM Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
May 6, 2021 08:00AM Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
Apr 30, 2021 09:28AM Pre-Open Stock Movers 04/30: (LAUR) (WDC) (TEAM) Higher; (MVIS) (ARDX) (TWTR) Lower (more...)
Apr 29, 2021 05:31PM After-Hours Stock Movers 04/29: (TEAM) (LAUR) (AMZN) Higher; (MVIS) (ARDX) (CRUS) Lower (more...)
Apr 29, 2021 05:02PM Xeris Pharma (XERS) Receives U.K. MHRA Approval of Ogluo for Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
Apr 29, 2021 04:05PM Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mel
Apr 1, 2021 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 11, 2021 07:07AM Xeris Pharmaceuticals (XERS) Prices $27 Million Registered Direct Offering of Common Stock at $4.12/sh
Mar 11, 2021 07:00AM Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering
Mar 9, 2021 07:00AM Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights
Mar 2, 2021 08:00AM Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021
Feb 26, 2021 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 18, 2021 08:00AM Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
View More Recent Stories View Older Stories